company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3809000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3809000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3809000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,907000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3875000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4782000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-973000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,97000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,28000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-68000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1041000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1045000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1045000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1045000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,100000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-11.68
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,100000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-11.68
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,89438.0
Regulus Therapeutics Inc,RGLS,,0001505512,2011.0,Q3,2011-07-01,2011-09-30,2012-11-19 16:02:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-11.68
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3344000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3344000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3344000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,921000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4603000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5524000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2180000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,93000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,27000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-66000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2246000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2247000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2247000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2247000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-13.06
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-13.06
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,171998000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q1,2012-01-01,2012-03-31,2013-05-14 18:59:37+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-13.06
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3309000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3309000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3309000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,984000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4883000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5867000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2558000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,90000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,27000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-63000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2621000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-22000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2599000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2599000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2599000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-10.78
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-10.78
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,241223000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q2,2012-04-01,2012-06-30,2013-08-13 19:28:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-10.78
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2809000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2809000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2809000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1093000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5248000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6341000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3532000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1848000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,20000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-331000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2159000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5691000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-6000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5685000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5685000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5685000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,355735000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-15.98
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,355735000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-15.98
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,400000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q3,2012-07-01,2012-09-30,2013-11-13 18:12:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-15.98
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3238000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3238000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3238000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1934000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5608000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7542000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4304000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-46000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,36000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2638000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2556000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6860000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,17000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6877000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6877000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6877000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,8200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,37.7
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,8200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,37.7
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,8212538.0
Regulus Therapeutics Inc,RGLS,,0001505512,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,37.7
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3238000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3238000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3238000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1905000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6883000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8788000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5550000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,72000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1761000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1689000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7239000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-10000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7229000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7229000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7229000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36100000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36100000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35872606.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 18:55:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4759000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4759000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4759000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1723000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7722000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9445000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4686000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,63000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2697000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2652000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7338000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7348000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7348000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7348000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,35994642.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,35994642.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q2,2013-04-01,2013-06-30,2014-08-06 17:58:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6118000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6118000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6118000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1917000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7106000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9023000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2905000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,72000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,671000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,736000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2169000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-5000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2164000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2164000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2164000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,40154812.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.05
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41555660.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.07
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43300000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q3,2013-07-01,2013-09-30,2014-11-05 18:09:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.05
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5454000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5454000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5454000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1884000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8231000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10115000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4661000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,85000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2642000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2716000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-1945000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-1927000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1927000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1927000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,38100000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.04
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,38100000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,38479447.0
Regulus Therapeutics Inc,RGLS,,0001505512,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.04
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1631000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1631000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1631000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2732000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9604000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12336000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10705000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,100000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2124000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2035000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-12740000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-12741000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-12741000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-12741000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,42500000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.3
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,42500000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.3
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42690200.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q1,2014-01-01,2014-03-31,2015-05-07 18:07:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.3
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,736000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,736000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,736000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2954000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10795000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13749000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13013000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,97000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,953000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1040000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11973000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11973000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11973000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11973000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43362483.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.28
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44799536.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.29
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42800000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 17:56:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.28
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1083000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1083000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1083000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2569000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10173000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12742000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11659000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,10000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,86000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1785000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1861000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9798000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9798000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9798000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9798000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43406251.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.23
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,44855463.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,42600000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q3,2014-07-01,2014-09-30,2015-11-05 18:15:42+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.23
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4219000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4219000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4219000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3278000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10474000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13752000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9533000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,105000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-12714000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-12617000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22168000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22168000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22168000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22168000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43900000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.48
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43900000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.44
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,44090165.0
Regulus Therapeutics Inc,RGLS,,0001505512,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.48
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3644000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13427000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17071000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12871000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,199000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1811000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1620000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14491000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-4000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14487000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14487000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14487000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.29
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.29
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50071165.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q1,2015-01-01,2015-03-31,2016-05-02 18:10:08+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3834000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3834000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3834000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5814000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19201000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,25015000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21181000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,7000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,151000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,144000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21037000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-2000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21035000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21035000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21035000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51300000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51300000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51073488.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q2,2015-04-01,2015-06-30,2016-08-02 18:03:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1865000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1865000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1865000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4245000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10965000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15210000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13345000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,6000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,335000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,329000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13016000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-16000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51990460.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q3,2015-07-01,2015-09-30,2016-11-01 18:21:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10860000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10860000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10860000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5427000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12794000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18221000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7361000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,31000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,170000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,139000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-7222000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7226000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7226000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7226000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51600000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51600000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51411353.0
Regulus Therapeutics Inc,RGLS,,0001505512,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,489000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,489000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,489000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5103000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16764000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21867000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21378000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,24000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,190000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,166000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21212000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-5000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21207000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21207000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21207000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,53000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.4
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.4
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52710672.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 20:36:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.4
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,483000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,483000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,483000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3664000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18007000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21671000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21188000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,90000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,180000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,90000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21098000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-8000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21090000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21090000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21090000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.4
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.4
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52782643.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q2,2016-04-01,2016-06-30,2017-08-01 18:15:25+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.4
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,204000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,204000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,204000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4842000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14554000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19396000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19192000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,560000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,237000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-323000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19515000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19519000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19519000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19519000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52800000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.37
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52800000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.37
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52835414.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 17:38:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.37
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4782000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14980000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19762000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19744000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,508000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,237000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-271000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20015000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,5000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20020000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20020000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20020000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,4400000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-4.55
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,4400000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-4.55
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,4401701.0
Regulus Therapeutics Inc,RGLS,,0001505512,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-4.55
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,36000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,36000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,36000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3959000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15752000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19711000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19693000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,546000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,214000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-332000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-20025000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-4000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-20021000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-20021000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-20021000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.38
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.38
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52990383.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:17:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.38
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7057000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14278000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21335000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21317000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,603000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,184000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-419000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21736000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-128000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21608000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21608000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21608000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.41
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.41
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,53182330.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 17:08:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.41
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2736000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12697000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15433000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15415000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,580000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,160000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-420000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15835000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-7000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15828000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15828000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15828000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,7500000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.11
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,7500000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.11
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,7506529.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:38:47+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.11
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3259000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10465000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13724000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13706000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,994000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,194000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-800000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14506000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-58000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14448000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14448000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14448000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,6300000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-2.29
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,6300000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-2.29
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,6269758.0
Regulus Therapeutics Inc,RGLS,,0001505512,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-2.29
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3773000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11828000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15601000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15583000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,605000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,164000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-441000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16024000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16025000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16025000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16025000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,8700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.85
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,8700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.85
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,8668695.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 19:23:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.85
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3349000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10013000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13362000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13344000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,621000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,118000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-503000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13847000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13847000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13847000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13847000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,8700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.59
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,8700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.59
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,8693788.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:51:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.59
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2993000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6879000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9872000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9854000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,620000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,201000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-419000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10273000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10273000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10273000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10273000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,8700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.18
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,8700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.18
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,8703626.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q3,2018-07-01,2018-09-30,2019-11-12 16:28:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.18
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2745000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5255000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8000000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7982000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,497000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-24000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-521000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8503000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,61000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8564000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8564000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8564000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,8700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.98
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,8700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.98
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,8718563.0
Regulus Therapeutics Inc,RGLS,,0001505512,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.98
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6778000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6778000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6778000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3533000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5983000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9516000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2738000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,578000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,56000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-522000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3260000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3260000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3260000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3260000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,10500000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.31
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,10500000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.31
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,10379830.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q1,2019-01-01,2019-03-31,2020-05-14 16:36:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.31
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2850000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1836000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4686000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4668000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,538000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,191000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-347000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5015000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5016000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5016000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5016000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,16700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.3
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,16700000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.3
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,16705587.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:51:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.3
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2571000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2440000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5011000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4993000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,517000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,87000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-430000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5423000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5423000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5423000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5423000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20900000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20900000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20849083.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q3,2019-07-01,2019-09-30,2019-11-12 16:28:01+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2363000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2090000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4453000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4435000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,498000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,40000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-458000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4893000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4893000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4893000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4893000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,17200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.28
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,17200000.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.28
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,17260176.0
Regulus Therapeutics Inc,RGLS,,0001505512,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.28
